Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|August 2, 2014
- Pharmaceutical Technology-08-02-2014
- Volume 37
- Issue 8
Pharmaceutical Technology, August 2014 Issue (PDF)
Click the title above to open the Pharmaceutical Technology August 2014 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 12 years ago
Risk Reduction Top Driver for Biopharmaceutical Raw Material Developmentabout 12 years ago
Changes and Challenges for Generic Drugsabout 12 years ago
Relationship-building at Top of Mind for Clientsabout 12 years ago
Complying with Revised Weighing Guidelinesabout 12 years ago
Pharma Investments Reflect Key Industry Trendsabout 12 years ago
Comparing Manufacturing Process Optionsabout 12 years ago
Implementing Supply-Chain Securityabout 12 years ago
Bioavailability Enhancement with Lipid-Based Drug-Delivery SystemsAdvertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5